Search

Der Preis des kostspieligen Krebsmedikaments Keytruda sorgt für rechtliche Kontroversen in Österreich, da mehrere Landesverwaltungsgerichte unterschiedlich entschieden haben, ob dieser Preis veröffentlicht werden muss, was nun den Verfassungsgerichtshof (VfGH) beschäftigt. #Keytruda #Medikamentenpreise #VfGH

Le coût élevé du traitement anticancéreux Keytruda, s'élevant à 70.000 euros par patient et représentant la plus grande dépense remboursée par la Sécurité sociale en France, suscite des débats sur l'accessibilité et la nécessité d'investissements accrus dans l'innovation pharmaceutique, malgré les plaintes des laboratoires concernant les coupes budgétaires. #MédicamentsInnovants #Sécu #SantéPublique

25-year-old Abdul Karim is urgently fighting relapsed Hodgkin lymphoma in Bulgaria. Doctors insist he must start Keytruda treatment next week. You can now support him through DMS: 📱 SMS with text DMS ABDUL KARIM to 17 777 or donate here: https://t.co/jtgEsRPvfw #HodgkinLymphoma #Keytruda #SupportAbdul #BG

25-year-old Abdul Karim is fighting relapsed Hodgkin lymphoma in Bulgaria. Doctors insist he must start Keytruda treatment next week. €5273 are urgently needed for the first cycle of chemotherapy. Full treatment is €22 000 Please help or share: https://t.co/eLZl4RJGRp #HodgkinLymphoma #Keytruda #CancerTreatment #BG

Der Artikel berichtet über die Bemühungen von DER STANDARD und profil, den geheimen Preis von Keytruda, dem teuersten Krebsmedikament der Welt, durch Informationsfreiheitsanträge vor neun Landesverwaltungsgerichten in Österreich zu ermitteln, während der Pharmakonzern MSD und andere Parteien juristisch gegen diese Transparenz vorgehen. #Keytruda #Gesundheitssystem #Informationsfreiheit

Health Minister Mike Nesbitt has announced that pembrolizumab (Keytruda), an injectable immunotherapy drug for multiple cancers, is currently available in three of Northern Ireland's five health trusts, with plans to expand access to all trusts soon, offering a quicker and less intrusive treatment option compared to traditional intravenous administration. #CancerTreatment #Immunotherapy #HealthCare #GB #NI #WA

Health Minister Mike Nesbitt has announced that the injectable cancer immunotherapy drug Pembrolizumab (Keytruda) is already being used in three of Northern Ireland's five health trusts, streamlining treatment for patients with multiple cancers and aiming for broader availability across all trusts soon. #CancerTreatment #Immunotherapy #HealthInnovation #GB #NI #WA #EN

Health Minister Mike Nesbitt has confirmed that pembrolizumab (Keytruda), an injectable immunotherapy drug for cancer treatment, is currently being used in three of Northern Ireland's five health trusts, with plans for broader availability to enhance patient care and reduce treatment time. #Immunotherapy #CancerTreatment #HealthcareInnovation #GB #NI #WA #EN

Health Minister Mike Nesbitt confirmed that the injectable cancer drug pembrolizumab (Keytruda), an immunotherapy used to treat multiple cancers, is already available in three of Northern Ireland's five health trusts, with plans for broader implementation to improve patient treatment efficiency. #CancerTreatment #Immunotherapy #HealthInnovation #GB #NI #ENG #WLS

Health Minister Mike Nesbitt has confirmed that the injectable cancer drug pembrolizumab (Keytruda) is already being used in three of Northern Ireland's five health trusts, with plans for expansion, as it offers a quicker and less invasive treatment option compared to the traditional intravenous infusion method. #CancerTreatment #Immunotherapy #HealthcareInnovation #GB #NI #WA #ENG

Health Minister Mike Nesbitt announced that the injectable cancer drug pembrolizumab (Keytruda), an immunotherapy treatment for multiple cancers, is already being administered in three of Northern Ireland’s five health trusts, with plans to expand its availability soon, following its recent approval for faster and less intrusive use compared to traditional intravenous methods. #CancerTreatment #Immunotherapy #HealthCare #GB #NI #WLS

Health Minister Mike Nesbitt announced that pembrolizumab (Keytruda), an injectable immunotherapy cancer drug, is already in use at three of Northern Ireland's five health trusts, with plans for broader availability, following its rollout in England and Wales, aiming to enhance treatment efficiency and patient care. #CancerTreatment #Immunotherapy #HealthcareTechnology #GB #NI #ENG #WLS

A new injectable form of the cancer drug Keytruda is set to significantly reduce hospital time for NHS patients in the UK, allowing them to receive the treatment in just a couple of minutes rather than over an hour, which could transform the management of cancer care by making it more efficient and convenient. #CancerTreatment #Immunotherapy #HealthcareInnovation #GB #US

An international investigation reveals that Merck's commercial strategy for its cancer drug Keytruda, which costs over R$20,000 in Brazil, employs complex legal and pricing tactics to control access, thereby making it increasingly inaccessible to many patients worldwide, despite its significant role in treating various cancers and generating billions in revenue. #CancerTreatment #PharmaceuticalIndustry #HealthInequality

An international investigation reveals that pharmaceutical company Merck's commercial strategy for the cancer drug Keytruda has been obstructing access to treatment for many patients worldwide due to its exorbitant pricing and extensive patent protections. #CancerTreatment #PharmaceuticalIndustry #PatientAccess